Cargando…

Role of Biomarkers in the Development of PARP Inhibitors

Defects in DNA repair lead to genomic instability and play a critical role in cancer development. Understanding the process by which DNA damage repair is altered or bypassed in cancer may identify novel therapeutic targets and lead to improved patient outcomes. Poly(adenosine diphosphate-ribose) pol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganguly, Bratati, Dolfi, Sonia C., Rodriguez-Rodriguez, Lorna, Ganesan, Shridar, Hirshfield, Kim M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786099/ https://www.ncbi.nlm.nih.gov/pubmed/26997874 http://dx.doi.org/10.4137/BIC.S36679

Ejemplares similares

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers
por: Paratala, Bhavna S., et al.
Publicado: (2016)

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
por: Rojas, Veronica, et al.
Publicado: (2016)

Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells
por: Dolfi, Sonia C, et al.
Publicado: (2017)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Targetable alterations in invasive pleomorphic lobular carcinoma of the breast
por: Riedlinger, Gregory M., et al.
Publicado: (2021)

Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology
por: Foran, David J, et al.
Publicado: (2017)

Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer
por: Dhami, Jatinder, et al.
Publicado: (2018)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer
por: Glod, John, et al.
Publicado: (2014)

Role of Akt Activation in PARP Inhibitor Resistance in Cancer
por: Gallyas, Ferenc, et al.
Publicado: (2020)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage
por: Ginjala, Vasudeva, et al.
Publicado: (2017)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes
por: Mehta, Madhura S., et al.
Publicado: (2013)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
por: Murthy, Pooja, et al.
Publicado: (2019)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors
por: Sobczak, Maciej, et al.
Publicado: (2020)

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials
por: Xia, Mingyue, et al.
Publicado: (2021)

Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs
por: Dolfi, Sonia C., et al.
Publicado: (2014)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_salce8368tgdp5kict7ndfaspm